De la Analítica al Social Media Intelligence : Una nueva oportunidad de liderar el mercado mediante una importante ventaja competitiva : saber identificar las necesidades del cliente en el Social Media : La reinvención de las investigaciones de mercado

La revolución que significó Internet a finales del siglo XX supone una oportunidad inmensa para el mundo corporativo. Con la aparición del Social Media y, en concreto, de las redes sociales, se han abierto un sinfín de nuevas oportunidades.No existe ningún otro invento que haya penetrado con tanta facilidad como lo han hecho estas plataformas; es el momento de que las empresas saquen provecho de ello.El objetivo principal de este proyecto consiste en identificar los beneficios potenciales para las empresas que conlleva actuar a través del Social Media. No contentos con eso, nos disponemos a mostrar las grandes razones por las que actuar: la posibilidad deidentificar las necesidades de tu público objetivo, huecos en el mercado y, por consiguiente, conseguir una ventaja competitiva clave en tu sector. ¿Cómo? La clave está en saber gestionar grandes volúmenes de información aplicando soluciones de inteligencia competitiva.Teniendo en cuenta que el proyecto gira entorno al Social Media, la estructura del mismo está dividida en dos grandes partes: en primer lugar estudiamos las claves de la investigación de mercados actual y, seguidamente, utilizamos una perspectiva más corporativa para mostrar las principales inquietudes que surgen en las empresas.Mediante ejemplos de casos prácticos muy relevantes, estudios que aporten datos clave y, sobre todo, las opiniones de profesionales del sector dentro y fuera de España, seremos capaces de deducir la importancia que tiene este terreno, así como el largo camino que nos queda a todos por delante.

Risk factor profile and management of cerebrovascular patients in the REACH Registry.

BACKGROUND: Cerebrovascular disease (CVD) is a global public health problem. CVD patients are at high risk of recurrent stroke and other atherothrombotic events. Prevalence of risk factors, comorbidities, utilization of secondary prevention therapies and adherence to guidelines all influence the recurrent event rate. We assessed these factors in 18,992 CVD patients within a worldwide registry of stable outpatients. METHODS: The Reduction of Atherothrombosis for Continued Health Registry recruited >68,000 outpatients (44 countries). The subjects were mainly recruited by general practitioners (44%) and internists (29%) if they had symptomatic CVD, coronary artery disease, peripheral arterial disease (PAD) and/or >or=3 atherothrombotic risk factors. RESULTS: The 18,992 CVD patients suffered a stroke (53.7%), transient ischemic attack (TIA) (27.7%) or both (18.5%); 40% had symptomatic atherothrombotic disease in >or=1 additional vascular beds: 36% coronary artery disease; 10% PAD and 6% both. The prevalence of risk factors at baseline was higher in the TIA subgroup than in the stroke group: treated hypertension (83.5/82.0%; p = 0.02), body mass index >or=30 (26.7/20.8%; p < 0.0001), hypercholesterolemia (65.1/52.1%; p < 0.0001), atrial fibrillation (14.7/11.9%; p < 0.0001) and carotid artery disease (42.3/29.7%; p < 0.0001). CVD patients received antiplatelet agents (81.7%), oral anticoagulants (17.3%), lipid-lowering agents (61.2%) and antihypertensives (87.9%), but guideline treatment targets were frequently not achieved (54.5% had elevated blood pressure at baseline, while 4.5% had untreated diabetes). CONCLUSIONS: A high percentage of CVD patients have additional atherothrombotic disease manifestations. The risk profile puts CVD patients, especially the TIA subgroup, at high risk for future atherothrombotic events. Undertreatment is common worldwide and adherence to guidelines needs to be enforced.

Evaluación participativa y empoderamiento: análisis documental de investigaciones y prácticas

Este artículo presenta los resultados de un trabajo de investigación y análisis documental sobre la evaluación participativa y el empoderamiento, realizado a investigaciones, proyectos yexperiencias a nivel nacional e internacional, desarrollados en la última década (entre el 2000 y2010 inclusive). Se describe el proceso de búsqueda en bases de datos -en el ámbito de lasciencias sociales -, de registro y de análisis, desarrollado por un equipo interuniversitario deinvestigadores en el marco de un I+D.El objetivo final de este trabajo no solo se centra en recabar y actualizar bibliografía en materiade evaluación participativa y de empoderamiento, sino en analizar los contenidos de las acciones descritas en los registros seleccionados.

Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study.

BACKGROUND: Ischemic stroke is the leading cause of mortality worldwide and a major contributor to neurological disability and dementia. Terutroban is a specific TP receptor antagonist with antithrombotic, antivasoconstrictive, and antiatherosclerotic properties, which may be of interest for the secondary prevention of ischemic stroke. This article describes the rationale and design of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic Attack (PERFORM) Study, which aims to demonstrate the superiority of the efficacy of terutroban versus aspirin in secondary prevention of cerebrovascular and cardiovascular events. METHODS AND RESULTS: The PERFORM Study is a multicenter, randomized, double-blind, parallel-group study being carried out in 802 centers in 46 countries. The study population includes patients aged > or =55 years, having suffered an ischemic stroke (< or =3 months) or a transient ischemic attack (< or =8 days). Participants are randomly allocated to terutroban (30 mg/day) or aspirin (100 mg/day). The primary efficacy endpoint is a composite of ischemic stroke (fatal or nonfatal), myocardial infarction (fatal or nonfatal), or other vascular death (excluding hemorrhagic death of any origin). Safety is being evaluated by assessing hemorrhagic events. Follow-up is expected to last for 2-4 years. Assuming a relative risk reduction of 13%, the expected number of primary events is 2,340. To obtain statistical power of 90%, this requires inclusion of at least 18,000 patients in this event-driven trial. The first patient was randomized in February 2006. CONCLUSIONS: The PERFORM Study will explore the benefits and safety of terutroban in secondary cardiovascular prevention after a cerebral ischemic event.

AltitudeOmics: enhanced cerebrovascular reactivity and ventilatory response to CO2 with high-altitude acclimatization and reexposure.

The present study is the first to examine the effect of high-altitude acclimatization and reexposure on the responses of cerebral blood flow and ventilation to CO2. We also compared the steady-state estimates of these parameters during acclimatization with the modified rebreathing method. We assessed changes in steady-state responses of middle cerebral artery velocity (MCAv), cerebrovascular conductance index (CVCi), and ventilation (V(E)) to varied levels of CO2 in 21 lowlanders (9 women; 21 ± 1 years of age) at sea level (SL), during initial exposure to 5,260 m (ALT1), after 16 days of acclimatization (ALT16), and upon reexposure to altitude following either 7 (POST7) or 21 days (POST21) at low altitude (1,525 m). In the nonacclimatized state (ALT1), MCAv and V(E) responses to CO2 were elevated compared with those at SL (by 79 ± 75% and 14.8 ± 12.3 l/min, respectively; P = 0.004 and P = 0.011). Acclimatization at ALT16 further elevated both MCAv and Ve responses to CO2 compared with ALT1 (by 89 ± 70% and 48.3 ± 32.0 l/min, respectively; P < 0.001). The acclimatization gained for V(E) responses to CO2 at ALT16 was retained by 38% upon reexposure to altitude at POST7 (P = 0.004 vs. ALT1), whereas no retention was observed for the MCAv responses (P > 0.05). We found good agreement between steady-state and modified rebreathing estimates of MCAv and V(E) responses to CO2 across all three time points (P < 0.001, pooled data). Regardless of the method of assessment, altitude acclimatization elevates both the cerebrovascular and ventilatory responsiveness to CO2. Our data further demonstrate that this enhanced ventilatory CO2 response is partly retained after 7 days at low altitude.

Systematic surgical closure of patent foramen ovale in selected patients with cerebrovascular events due to paradoxical embolism. Early results of a preliminary study.

OBJECTIVE: To define therapeutic strategy for management of patients with ischemic stroke due to a high probability of paradoxical embolism through a Patent Foramen Ovale (PFO). METHODS: Since 1988 all consecutive patients with cerebrovascular events and PFO from the Stroke Registry of our population-based primary-care center are prospectively studied and followed. Since 1992, among 118 patients with cryptogenic embolic brain infarct or transient ischemic attack (TIA) and PFO, 32 consecutive patients younger than 60 years who presented at least two of the following criteria were admitted for surgery: history of Valsalva strain before stroke (11); multiple clinical events (13); multiple infarcts on brain Magnetic Resonance Imaging (MRI) (15); atrial septal aneurysm (ASA) (16); large right-to-left shunt (> 50 microbubbles) (12). RESULTS: Operative time 135' +/- 33'. CPB time 34' +/- 14'. Aortic crossclamping time 16' +/- 6'. Post-operative bleeding 485 +/- 170 ml. No homologous blood transfusion required. No neurological, cardiac or renal complications. All patients were followed-up corresponding to a cumulative time of 601 patient-months. This revealed no recurrent vascular events nor silent new brain lesions on brain MRI. Systematic simultaneous contrast Trans Esophageal Echocardiography (TEE)-Trans Cranial Doppler showed a small residual interatrial shunt in two patients. CONCLUSION: Surgical closure of a patent foramen ovale can be accomplished with very low morbidity and reduce efficiently the risk of stroke recurrence. It seems to be the option of choice in selected patients with a higher (> 1.5%/year) risk of stroke recurrence.

Acute ischemic cerebrovascular events on antiplatelet therapy: what is the optimal prevention strategy?

Even though patients who develop ischemic stroke despite taking antiplatelet drugs represent a considerable proportion of stroke hospital admissions, there is a paucity of data from investigational studies regarding the most suitable therapeutic intervention. There have been no clinical trials to test whether increasing the dose or switching antiplatelet agents reduces the risk for subsequent events. Certain issues have to be considered in patients managed for a first or recurrent stroke while receiving antiplatelet agents. Therapeutic failure may be due to either poor adherence to treatment, associated co-morbid conditions and diminished antiplatelet effects (resistance to treatment). A diagnostic work up is warranted to identify the etiology and underlying mechanism of stroke, thereby guiding further management. Risk factors (including hypertension, dyslipidemia and diabetes) should be treated according to current guidelines. Aspirin or aspirin plus clopidogrel may be used in the acute and early phase of ischemic stroke, whereas in the long-term, antiplatelet treatment should be continued with aspirin, aspirin/extended release dipyridamole or clopidogrel monotherapy taking into account tolerance, safety, adherence and cost issues. Secondary measures to educate patients about stroke, the importance of adherence to medication, behavioral modification relating to tobacco use, physical activity, alcohol consumption and diet to control excess weight should also be implemented.

Investigaciones sobre la detección, difusión natural y control del enrollamiento clorótico del albaricoquero

Se ha aplicado la técnica de la tinción con el fluorocromo DAPI (4'-6- diamidino- 2-fenilindol) a la detección de organismos del tipo micoplasma («mycoplasma-like organisms» o MLOs) y al seguimiento, a lo largo de un año, de la distribución de MLOs en albaricoqueros enfermos de enrollamiento clorótico («apricot chloroiic leaf roll» o ACLR). Los resultados obtenidos confirman la poca fiabilidad de esta técnica para la detección precoz de micoplasmosis en árboles frutales, a causa de la baja concentración e irregular distribución de MLOs dentro de los árboles enfermos. Én cambio, la tinción con DAPI es útil para la observación a lo largo del año de la distribución de MLOs en diferentes partes de los árboles infectados por ACLR. A lo largo del invierno y la primavera, los MLOs fueron detectados solamente en las raíces y en los ramos formados el año anterior. La presencia de MLOs en los nuevos brotes no pudo ser detectada hasta el principio del verano. En trabajos previos se observaron grandes variaciones en la difusión natural del ACLR, incluso entre áreas próximas de la misma provincia de Valencia. Las investigaciones efectuadas ahora sobre las poblaciones de cicadélidos han mostrado que tanto el número de especies como el de individuos capturados son superiores en un área con una importante difusión natural del ACLR que en otra zona donde la difusión de la enfermedad es prácticamente nula. Las diferencias entre los cicadélidos capturados en estas dos áreas han proporcionado indicaciones acerca de las especies que tienen más probabilidades de ser vectores del ACLR. Se ha estudiado también, durante tres años, la influencia de tratamientos insecticidas y herbicidas sobre la difusión natural del ACLR en una plantación de albaricoqueros. En la mitad de la plantación que se dejó sin tratar, el número de cicadélidos capturados, así como el de nuevos árboles con síntomas de ACLR fue mayor que en la parte de la plantación que había sido tratada.

Thromboxane prostaglandin receptor antagonist and carotid atherosclerosis progression in patients with cerebrovascular disease of ischemic origin: a randomized controlled trial.

BACKGROUND AND PURPOSE: Thromboxane prostaglandin receptors have been implicated to be involved in the atherosclerotic process. We assessed whether Terutroban, a thromboxane prostaglandin receptor antagonist, affects the progression of atherosclerosis, as measured by common carotid intima-media thickness and carotid plaques. METHODS: A substudy was performed among 1141 participants of the aspirin-controlled Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients with a History of Ischemic Stroke or Transient Ischemic Attack (PERFORM) trial. Common carotid intima-media thickness and carotid plaque occurrence was measured during a 3-year period. RESULTS: Baseline characteristics did not differ between Terutroban (n=592) and aspirin (n=549) treated patients and were similar as in the main study. Mean study and treatment duration were similar (28 and 25 months, respectively). In the Terutroban group, the annualized rate of change in common carotid intima-media thickness was 0.006 mm per year (95% confidence interval, -0.004 to 0.016) and -0.005 mm per year (95% confidence interval, -0.015 to 0.005) in the aspirin group. There was no statistically significant difference between the groups in the annualized rate of change of common carotid intima-media thickness (0.011 mm per year; 95% confidence interval, -0.003 to 0.025). At 12 months of follow-up, 66% of Terutroban patients had no emergent plaques, 31% had 1 to 2 emergent plaques, and 3% had ≥3 emergent plaques. In the aspirin group, the corresponding percentages were 64%, 32%, and 4%. Over time, there was no statistically significant difference in the number of emergent carotid plaques between treatment modalities (rate ratio, 0.91; 95% confidence interval, 0.77-1.07). CONCLUSIONS: Compared with aspirin, Terutroban did not beneficially affect progression of carotid atherosclerosis among well-treated patients with a history of ischemic stroke or transient ischemic attacks with an internal carotid stenosis <70%. CLINICAL TRIAL REGISTRATION URL: http://www.controlled-trials.com. Unique identifier: ISRCTN66157730.

Telerehabilitació en pacients amb accidents cerebrovascular: revisió bibliogràfica.

L’ ictus és una alteració brusca de la circulació de la sang al cervell, sent la segona causa de mort al món i la primera en discapacitat. Objectius. Examinar si la telerehabilitació i la realitat virtual poden millorar l'estat físic i psíquic dels pacients amb accident cerebrovascular i avaluar l’impacte en les activitats de la vida diària. Conclusió. Els resultats indiquen que la fisioteràpia convencional i un programa combinat de telerehabilitació o realitat virtual amb fisioteràpia, milloren les capacitats físiques dels pacients, no obstant, el tractament combinat obté millores significativament superiors al tractament convencional. La tecnologia en l’àmbit de la rehabilitació pot ser una alternativa segura per promoure la recuperació motora després d'un accident cerebrovascular.

Tómese unos minutos para revisar sus conocimientos sobre: Enfermedad cerebrovascular/circulación cerebral

1. ¿Cuál de las siguientes arterias no forma parte del territorio carotídeo? a. Arteria cerebral posterior, b. Carótida interna, c. Arteria cerebral media, d. Arteria ...